Proteomics in melanoma biomarker discovery: great potential, many obstacles.
Proteomics in melanoma biomarker discovery: great potential, many obstacles.
复制标题
DOI：
10.1155/2011/181890
复制
发表时间：
2011-01-01
期刊：
影响因子：
--
通讯作者：
Lubman, David M
中科院分区：
文献类型：
--
作者：
Sabel, Michael S;Liu, Yashu;Lubman, David M
目前黑色素瘤的临床分期将患者分为异质性组，导致对大人群应用积极治疗，稀释影响并增加毒性。为了进入基于高度特异性肿瘤谱的治疗决策的新时代，发现和验证黑色素瘤中新的预后和预测生物标志物至关重要。在其他实体瘤中显示出希望的基因组分析需要来自大量原发性肿瘤的新鲜组织，因此在黑色素瘤中面临独特的挑战。由于这个和其他原因，蛋白质组学似乎是发现新的黑色素瘤生物标志物的理想选择。蛋白质组学的几种方法已被用于寻找临床相关的生物标志物，但迄今为止，结果相对有限。本文将回顾目前的工作，使用组织和血清蛋白质组学在寻找黑色素瘤的生物标志物，突出每种方法的相对优势和劣势。此外，我们审查了几个主要的障碍，需要克服，以推进该领域。
The present clinical staging of melanoma stratifies patients into heterogeneous groups, resulting in the application of aggressive therapies to large populations, diluting impact and increasing toxicity. To move to a new era of therapeutic decisions based on highly specific tumor profiling, the discovery and validation of new prognostic and predictive biomarkers in melanoma is critical. Genomic profiling, which is showing promise in other solid tumors, requires fresh tissue from a large number of primary tumors, and thus faces a unique challenge in melanoma. For this and other reasons, proteomics appears to be an ideal choice for the discovery of new melanoma biomarkers. Several approaches to proteomics have been utilized in the search for clinically relevant biomarkers, but to date the results have been relatively limited. This article will review the present work using both tissue and serum proteomics in the search for melanoma biomarkers, highlighting both the relative advantages and disadvantages of each approach. In addition, we review several of the major obstacles that need to be overcome in order to advance the field.